News Column

BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn

July 11, 2014

BrainStorm Cell Therapeutics, Inc.

PETACH TIKVAH, ISRAEL and NEW YORK, NY, United States, via eTeligis Inc., 07/11/2014 - - BrainStormCell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journalClinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration ofNurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety ofneurotrophicfactors.NurOwnis in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease,Huntingon'sdisease and multiple sclerosis. The results published today are important because they establish that repeated doses ofNurOwnare safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure toNurOwn, which are human cells. These data will help support the use of multiple doses ofNurOwnin future clinical trials.



One of the major goals of this study was to determine if normal mice develop an immune response toNurOwnafter repeated exposures to the cells.The study assessed a variety of Th1 and Th2 cytokines in these mice, which have a normally functioning immune system, and observed only transient increases in interleukin (IL)-5, IL-6 and to a lesser extent IL-2, which returned to baseline within 24 hours after administration ofNurOwn. Importantly, IL-4 and IL-10, which are key regulators of the humoral immune response, were undetectable before and after treatment. Thus, there was no substantial or durable immune response toNurOwnafter two or three repeated administrations in mice, despite the fact that the cells were of human origin. In addition, the repeated administration ofNurOwnwas well-tolerated in these mice, with no evidence of systemic toxicity and minor irritation seen at the site of intramuscular administration.



Commenting on this publication,BrainStorm'sCEO TonyFiorino, MD, PhD, noted, "For the treatment of most neurodegenerative diseases, we expect that sustained benefit will require multiple doses ofNurOwn. Thus we are pleased to see such a benign safety profile in this study, and in particular the lack of an immune response in these mice to repeated exposure to human cells. These observations match the excellent safety profile that has been observed clinically in two ALS patients who have received two doses ofNurOwnat Hadassah Medical Center, under a Compassionate Use protocol approved by the Israeli Ministry of Health."



AboutBrainStormCell Therapeutics, Inc.

BrainStormCell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize itsNurOwntechnology through an exclusive, worldwide licensing agreement withRamot, the technology transfer company of Tel Aviv University. For more information, visit the company's website atwww.brainstorm-cell.com.



Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStormCell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential",andsimilar termsand phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated withBrainStorm'slimited operating history, history of losses; minimal working capital, dependence on its license toRamot'stechnology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed inBrainStorm'sannual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance onBrainStorm'sforward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.





CONTACT:



BrainStormCell Therapeutics Inc.

Mr. TonyFiorino

CEO

Phone: +972-3-9236384

info@brainstorm-cell.com



US InvestorContact

LifeSciAdvisors, LLC

Michael Rice

Phone: 646-597-6979

mrice@lifesciadvisors.com







SOURCE:BrainStormCell Therapeutics, Inc.




For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: eTeligis.com


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters